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Abstract (271 words): 
Objective: To investigate the risk of medical complications following total hip and knee 
arthroplasty (THA/TKA) among rheumatoid arthritis (RA) compared with osteoarthritis (OA) 
patients; and, to assess the risk of complications among biologics-treated RA patients. 
Methods: In a nationwide register-based study, patients with RA and OA with THA/TKA surgery 
between 2000 and 2015 were identified and followed up to 90 days after surgery for venous 
thromboembolism (VTE), myocardial infarction and stroke, and non-surgical infections, 
respectively. Information on treatment with biologics was obtained in the DANBIO rheumatology 
register to compare risks of complications with non-biologics treated. 
Results: A total of 2,899 and 112,571 patients with RA and OA had THA/TKA. RA was associated 
with a hazard ratio (HR) of 1.29 (1.03 to 1.61) for infection following THA/TKA, but a HR of 0.60 
(0.26 to 0.98) for VTE following TKA. Biologics treated patients had a HR of 1.35 (0.65 to 2.80) 
for infection and 4.82 (1.67 to 13.90) for VTE compared with non-biologics treated RA patients. 
RA patients had no increased risk of post-surgical myocardial infarction and stroke (HR 1.16, 0.76 
to 1.78) compared with OA, but a higher incidence proportion was observed in biologics treated 
compared with non-biologics treated (1.0 vs 0.6 %); however, the number of events were too small 
to estimate a HR. 
Conclusion: In this study, RA was a risk factor for infection after THA/TKA, and RA patients 
treated with biologics had a slightly increased risk compared with non-biologics treated RA 
patients. Compared with OA, RA patients had a lower risk of VTE following THA/TKA, but our 
















In non-surgical settings, patients with rheumatoid arthritis (RA) are at increased risk of infections, 
myocardial infarction, stroke and venous thromboembolism (VTE) compared with the general 
population [1–6].  
Total hip and total knee arthroplasty (THA/TKA) are regular procedures in patients with RA, and 
the increased risks of VTE, myocardial infarction and stroke, and infections could be further 
exacerbated following such major surgery.  
Patients selected for treatment with biological DMARDs (biologics) are at increased risk of 
infections with a time-dependent risk peaking immediately following treatment commencement but 
subsequently decrease to the level of RA patients not treated with biologics [7–9]. Perioperative 
adverse events in users of biologics is a major concern and the scientific literature has not provided 
clear answers as to whether that concern should be merited, but recent studies indicate no clear 
increased risk of prosthetic joint infection and mortality in those exposed to these drugs prior to 
surgery [10–12].  However, very few have looked at the risk of other infections than prosthetic joint 
infection while at the same time adjusting for disease activity and glucocorticoids, the two other 
major confounders when assessing these relations. Likewise, the potential impact of biologics on 
the risk of VTE and other cardiovascular events in a surgical setting is unknown. 
Thus, our aim was to investigate the risk of VTE, myocardial infarction and stroke, and non-
surgical site infections in patients with RA who had THA/TKA surgery in a population-based 














2. PATIENTS AND METHODS 
2.1 Design and setting 
This was a nationwide, register-based cohort study from Denmark, investigating the risk of serious 
medical complications following THA/TKA in patients with RA compared with OA; and, among 
biologics-treated patients compared with non-biologics treated RA patients. The study period ran 
from 2000 to the end of 2014. In Denmark healthcare is tax-funded and offers universal access for 
all residents, and unique personal identifiers assigned to all residents at birth or upon immigration 
allows for nationwide register-linkage. The study adheres to the STROBE guidelines [13].  
2.2 Data sources and study populations 
The Danish Hip and Knee Arthroplasty Registers (DHR and DKR) both hold detailed surgical 
information on > 96 % of primary THA and TKA surgeries performed in Denmark since 1995 and 
1997, respectively [14–17]. Among individuals registered with a first primary THA or TKA in the 
DHR or DKR between 2000 and end of 2014 [14,15], patients with RA were identified by linkage 
with the DANBIO rheumatology register, and the Danish National Patient Register (DNPR) using 
validated algorithms (Supplementary Table 1) [18]. 
DANBIO is a nationwide register used by rheumatologists in routine care of rheumatic patients 
since 2000 [19]. Registered information includes but is not limited to clinical history and progress 
along with information on treatment series with biologics, conventional synthetic DMARDs, and 
glucocorticoids. In DANBIO, the positive predictive value of an RA diagnosis is 96 %. However, 
the registration of patients not treated with biologics did not become mandatory before 2006. Thus, 
in order to include patients not treated with biologics within the full study period, the DNPR was 
also used to identify RA patients. DNPR was established in 1977 and since 1995, all in- and 













diagnoses are registered in accordance with the International Classification of Diseases 10
th
 version 
(ICD-10). In addition, all surgeries and procedures performed during a contact are also registered. 
We used a validated algorithm to identify RA patients in DNPR that were not registered in 
DANBIO: individuals were required to have at least two hospital contacts at a rheumatology or 
general internal medicine department listing RA as the main diagnosis and no more than 90 days 
apart. This algorithm has a PPV of at least 79 %[19]. 
The OA cohort comprised patients registered in DHR/DKR with OA listed as the main diagnosis 
and surgical indication, but with no previous RA diagnosis listed in DANBIO nor DNPR [21]. 
Biologics and non-biologics treated RA patients. We used information on start and stop dates for 
treatment episodes with biologics in DANBIO to identify patients treated with biologics within 90 
days prior to surgery. Information was obtained in the same manner for pre-operative exposure to 
conventional DMARDs and steroid treatments in the 90-day presurgical window. Clinical 
information on RA disease activity score (DAS28) and physical function (HAQ-DI) registered 
within 180 days prior to surgery was obtained. 
2.3 Outcomes 
There were three outcomes of interest: VTE, myocardial infarction and stroke, and infections (non-
surgical site). Outcome information was obtained in DNPR (Supplementary table 2 for ICD-10 
codes). Most of these outcomes have been validated with PPVs of ~70-90 % [20,22]. The 
composite infection outcome included occurrences of pneumonia, sepsis, urinary tract infection, 
and erysipelas. If patients experienced more than one infection, only the first one counted in the 
composite analysis. We specifically investigated infections that were in no way related to the 
surgical procedure nor the prosthetic material as this was the subject of a previous publication in 














We obtained vital status information from the Danish Civil Registration System [23]. For all 3 
outcomes, follow-up was limited to the first 90 days after surgery. In each analysis, patients were 
followed from the date of surgery until date of outcome of interest, death, emigration or 90 days 
post-surgery, whichever occurred first.  
2.5 Statistics 
RA compared with OA. Hazard ratios (HR) with 95 % confidence intervals (95%CI) were estimated 
in a crude and two multivariable Cox models: Model 1 was stratified by sex and adjusted for age at 
surgery and calendar period of surgery, whilst Model 2 included the covariates of Model 1 and was 
further stratified by type of surgery (THA vs TKA) and adjusted for duration of surgery and co-
morbidities: history of chronic obstructive pulmonary disease (COPD), previous VTE,  previous 
serious infections, cardiovascular disease (CVD), diabetes mellitus (DM) or cancer. Comorbidity 
information was obtained in DNPR using a 5-year lookback window for infections from the date of 
surgery and 10-year lookback windows for other comorbidities (Supplementary Table 3 for ICD-10 
codes). 
Biologics compared with non-biologics treated. The Cox proportional hazards model included only 
the biologics exposure covariate and the calculated propensity score (PS), i.e. the probability of 
receiving biologics conditional on confounders at the time of surgery, as a spline covariate with 5 
degrees of freedom. Covariates used in calculation of the PS included: age at surgery, sex, calendar 
period of surgery, pre-operative use of methotrexate, pre-operative use of other conventional 
DMARDs, pre-operative use of glucocorticoids, DAS28, HAQ-DI, VAS physician, COPD, DM, 
CVD, previous VTE, cancer, and previous serious infection. Due to few events in the comparison of 













Multiple imputation. Multiple imputation using chained equations (MICE) was undertaken to 
account for missing data in the perioperative window. Around 68 and 66 % had no information on 
DAS28 and HAQ-DI within 180 days prior to THA/TKA surgery. All covariates included in PS 
calculation were entered in the imputation model. Missing values of DAS28, HAQ-DI, tender and 
swollen joint count (using 28 joints), visual analogue scores (0-100) for physician assessment of 
overall disease burden, patient reported pain level, patient reported fatigue level, and CRP level 
were imputed using predictive mean matching. A total of 100 datasets were imputed and following 
Cox regression analyses within each dataset, the hazard ratios were combined according to Rubin’s 
Rules. Statistical analyses were performed in R Statistical Software 3.2.3.  
Sensitivity analyses. In analyses where the confidence interval did not cross unity, the E-value was 
calculated [24]. The E-value is a relatively new sensitivity measure that provides an estimate of the 
magnitude with which any unmeasured confounder would have to be associated with the outcome 
of interest in order to overcome or dismiss the exposure-outcome association of the presented 
analysis. It is a sensitivity analysis that requires no assumptions regarding the distribution of the 
confounder nor if it is a continuous or binary explanatory variable [25].  
Due to the non-negligible proportion of DANBIO patients that had missing data on DAS28 and 
HAQ-DI, we carried out a sensitivity analysis in which these covariates were not included in the 
propensity score estimation, and subsequently carried out the Cox models estimating the impact of 














RA compared with OA. 
We identified 2,899 and 112,571 patients with RA and OA who underwent THA or TKA surgery 
(Supplementary Figure 1 for patient flow-chart). Patients with RA were younger at the time of 
surgery (66.1 vs 69.1 years), more likely to be female (73 vs 58 %) and have TKA rather than THA 
surgery (TKA: 63 vs 44 % of surgeries in RA compared with OA) (Table 1).  In both cohorts, 99 % 
of patients received thromboprophylaxis with no difference in the duration of the therapy. RA 
patients more frequently had a history of COPD, cardiovascular disease including previous VTE 
events, and hospitalisations due to infection, whereas a higher proportion of OA patients had a 
history of cancer (Table 1).  
Patients with RA had a lower risk of deep vein thrombosis and pulmonary embolism and 
consequently VTE (Table 2).  This decreased risk was only driven by TKA surgery (HRTKA 0.60, 
0.26 to 0.98) (Supplementary Table 4). Excluding patients with a history of VTE, cancer or both did 
not substantially alter the HRs:  0.81 (0.56 to 1.18); 0.81 (0.56 to 1.17); and 0.89 (0.61 to 1.29), 
respectively. The decreased risk of VTE was more pronounced in male patients with RA (HR 0.48, 
95%CI 0.2 to 1.17). The E-value for the association between RA and VTE following TKA was 2.73  
The overall risk of post-surgical myocardial infarction and stroke was not increased among RA 
patients, but increased risk estimates were seen among female RA patients compared with OA (HR 
1.53, 0.91 to 2.56).  
Patients with RA had an increased risk of infection (HRModel2 1.29, 1.03 to 1.64) driven by risks of 
pneumonia, sepsis and erysipelas but not urinary tract infection. This finding was consistent across 













Biologics compared with non-biologics treated RA patients. 
A total of 411 patients received treatment with a biologic within 90 days preceding surgery (Table 
3). No difference in DAS28 was observed prior to surgery, but biologics-treated had higher median 
HAQ-DI. Biologics treated more frequently had a history of hospitalisation due to infection, 
whereas they less frequently had a history of cancer compared with their non-biologics treated 
counterparts. 
Following THA/TKA, biologics-treated had a higher incidence and risk of VTE compared with 
non-biologics treated (1.9 vs 0.5%; HR 4.82, 1.67 to 13.90) (Table 4). Excluding patients who had a 
history of cancer, VTE or either of the two, did not change the results: HRs 4.74 (1.64 to 13.75); 
4.76 (1.65 to 13.72); and, 4.70 (1.62 to 13.61), respectively. The calculated E-value was 9.1 
indicating that any unmeasured confounder would have to be associated with VTE at a relative risk 
of this magnitude to overcome the association between biologics treatment and VTE.  
A higher proportion of biologics-treated also suffered a myocardial infarction or stroke compared 
with non-biologics treated (1.0 vs 0.6 %), but with < 5 events registered in one group (4 and 8, 
respectively), no hazard ratio could be estimated.  
An increased risk of infection was observed among biologics treated compared with non-biologics 
treated patients (HR 1.35, 0.65 to 2.80).  Excluding patients previously hospitalised due to infection 
did not alter the HR, 1.38 (0.61 to 3.12). 
When omitting DAS28 and HAQ-DI from the propensity score estimation, the subsequent Cox 
models for VTE and infection resulted in HRs of 6.39 (95%CI 2.12 to 19.30) and 1.10 (95%CI 0.52 















In this nationwide study investigating the risk of serious medical complications following major 
joint surgery, patients with RA were at increased risk of infections following THA/TKA, and 
biologics treated RA patients had a higher risk estimate of infections compared with non-biologics 
treated RA patients. We found a lower risk of VTE among RA patients following TKA, but 
surprisingly, biologics treated had a ~5-fold increased risk of VTE compared to non-biologics 
treated RA patients. 
The finding of an increased risk of non-surgical site infections among RA patients following major 
surgery is in line with some [26,27], but not all previous studies.[28] Michaud et al. found no 
increased risk of infection up to 30 days after THA and TKA in a predominantly male RA cohort 
compared with OA patients [28]. Possible explanations for different findings could be the different 
follow-up period (30 vs 90 days in the present study) and/or the differences in sex composition and 
population size. In contrast, Cancienne et al. reported an odds ratio of 1.5 for infection within 90 
days of TKA in RA compared with OA in a study using Medicare data [26]. 
Biologics treated patients had a HR of 1.35 for infections compared with non-biologics treated RA 
patients but with wide confidence intervals. To our knowledge, only one study by Somayaji et al. 
has specifically investigated this matter, and they found no increased risk of non-surgical infections 
following THA/TKA in 70 TNFi treated compared with 189 non-TNFi treated patients [29]. 
The lower risk of VTE following TKA is intriguing given that RA is a well-established risk factor 
for VTE in a non-surgical setting [2,5,6]. The HR remained below 1 even after exclusion of all 
patients with a history of cancer and/ or previous VTE. In the present study, 99% of patients in both 
cohorts received thromboprophylaxis. Thus, we have no definite explanation for this finding which 













increased prevalence of obesity in the OA cohort, which was at least suggested by the higher mean 
weight among TKA recipients in the present study. It could also be that OA patients are more 
frequent users of NSAIDs than patients with RA [34]. 
In addition, we showed that biologics treated patients had a higher incidence of VTE compared with 
non-biologics treated patients, and the calculated E-value for this association was 9.1, suggesting 
that any unmeasured confounder would need to be associated with the outcome at this magnitude to 
overcome the presented result. confounder  A time-dependent increased risk of VTE has been 
reported for patients with RA commencing biologics treatment with a subsequent gradually 
normalisation of the risk [35]. Following orthopaedic surgery, a study using data from the BSRBR-
RA in the UK showed TNF-inhibitor treatment was associated with a statistical non-significant 
elevated odds ratio for VTE compared with non-biologics treated RA patients; the same pattern was 
observed in a study from Japan by Kawakami et al. [36,37]. The cumulative incidence of 1.9 % 
among biologics treated in our study is even higher than the 1.3 % observed in the OA cohort 
indicating that the risk is not merely “normalised” from the lower incidence of the entire RA cohort 
to an average level of the OA cohort, but that a possibly elevated risk truly exists. With the present 
results it is not possible to conclude if this risk is due to treatment with biologics or confounded by 
RA-severity markers for which we were unable to fully adjust, although interestingly, the DAS28 
did not differ between biologics and non-biologics treated.  
In line with some, [28] but not all previous studies [31,38], no short-term increased risk of 
myocardial infarction and stroke following THA/TKA was observed among patients with RA. Burn 
et al. recently reported an increased risk of myocardial infarction in patients with RA compared 
with OA up to 90 days following THA and TKA (adjusted HR 3.54, 1.44 to 8.73) [31]. The 
cumulative incidence of myocardial infarction in that RA cohort was 0.75 %, the same proportion 













the different outcome definitions (with and without stroke, respectively) and validity, as well as 
different origins of the RA populations (hospital vs general practice, respectively) are more likely to 
explain the different results. We do, however, also find it surprising that no increased risk of 
myocardial infarction and stroke was seen among patients with RA in the present study. 
There are limitations to the present study that needs mentioning. One such is the definition of 
biologics exposure used: Currently no validation exists of the start and stop dates for treatment 
series in DANBIO. This is also the reason why we did not investigate the impact on complications 
with presurgical continued or withholding of biologics. Further, the DANBIO data on DAS28 and 
HAQ-DI suffered from a non-negligible degree of missingness. Primarily, we carried out multiple 
imputation to account for this, but in a sensitivity analysis we omitted these confounders from the 
propensity score estimation, which did not change the direction of the risk estimates in the 
subsequent Cox models.   
Including and adjusting for the PS as a spline covariate is another limitation, although given the low 
number of events and the many important confounders, this was the most reasonable alternative. 
Another possible pitfall is the risk of misclassification bias in the subset of our RA cohort from 
DNPR. Whereas the positive predictive value (PPV) of an RA diagnosis in DANBIO has been 
estimated to ~97 %, a less strict definition of RA in DNPR than the one used in the present study 
had a PPV of ~80 % (Supplementary Table 1) [18]. 
The strengths of the present study include the nationwide design with independent reporting to 
health care registers and no loss to follow-up. The VTE and cardiovascular outcomes from DNPR 
have been validated and found to have high PPVs ranging from 70-100 % in DNPR [22]. Lastly, the 
detailed information on thromboprophylaxis in DHR and DKR along with the information on VTE 














In conclusion, we found that following THA/TKA surgery, RA was associated with increased risk 
of infections, mainly pneumonia, sepsis and erysipelas, compared with OA. RA patients treated 
with biologics had a slightly increased risk of infections compared with non-biologics treated RA 
patients. The risk of VTE was lower among RA compared with OA patients following TKA. 
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Table 1. Demographic, clinical and surgical characteristics of patients with rheumatoid arthritis (RA) and osteoarthritis 
(OA) who had a first primary elective total hip or total knee arthroplasty (THA and TKA) between 2000 and end of 2014. 
 
RA OA p Missing data 
N 2899 112 571 
  
Female sex, n (%) 2115 (73.0) 65 664 (58.3) <0.001 
 
Age at surgery, mean (sd) 66.1 (11.0) 69.1 (9.7) <0.001 0% 
Calendar period of 
surgery, n (%)  
2000 to 2002 531 (18.3) 16 110 (14.3) <0.001 0% 
2003 to 2005 554 (19.1) 18 797 (16.7) 
  
2006 to 2008 547 (18.9) 23 463 (20.8) 
  
2009 to 2011 638 (22.0) 27 928 (24.8) 
  
2012 to 2014 629 (21.7) 26 273 (23.3) 
  
Surgical characteristics  
Type of arthroplasty, 
n (%) 
THA 1062 (36.6) 62 637 (55.6) <0.001 0% 
TKA 1837 (63.4) 49 934 (44.4) 
  
Duration of surgery in minutes, median (IQR) 68 (59 to 83) 65 (55 to 80) <0.001 0% 
Duration of hospital stay in days, median (IQR) 5 (3 to 9) 4 (3 to 8) <0.001 0% 
Preoperative weight in kilograms  
(only reported for TKA recipients), mean (sd) 
75.7 (18.1) 83.4 (18.4) <0.001 
12% (of TKA 
recipients) 
Received thromboprophylaxis, % 2858 (99) 111 331 (99) 0.25 0% 
Duration of thromboprophylaxis in days, median 
(IQR) 
7 [4, 30] 7 [4, 30] 0.56 33% 
Comorbidities 
Chronic obstructive pulmonary disease, n (%) 197 (6.8) 4727 (4.2) <0.001 0% 
Previous VTE, n (%) 96 (3.3) 2624 (2.3) 0.001 0% 
Diabetes mellitus, n (%) 201 (6.9) 7603 (6.8) 0.51 0% 
Cardiovascular disease, n (%) 480 (16.6) 16 593 (14.7) 0.007 0% 
Previously diagnosed with cancer, n (%) 171 (5.9) 7819 (6.9) 0.03 0% 
Previously hospitalised due to infection, n (%) 279 (9.6) 4804 (4.3) <0.001 0% 















Table 2: Risk of complications after total hip and knee arthroplasty in rheumatoid arthritis compared with 
osteoarthritis patients. 
 
Rheumatoid arthritis,  
N = 2899 
Osteoarthritis,  
N = 112 571 



















30 1.03 1464 1.30 
0.80 (0.55 to 
1.14) 
0.83 (0.58 to 
1.19) 






25 0.86 1169 1.04 
0.83 (0.56 to 
1.23) 
0.86 (0.58 to 
1.28) 






5 0.17 331 0.29 
0.59 (0.24 to 
1.42) 
0.61 (0.25 to 
1.48) 






22 0.76 851 0.76 
1.00 (0.66 to 
1.53) 
1.28 (0.83 to 
1.95) 






79 2.73 2394 2.13 
1.28 (1.01 to 
1.61) 
1.50 (1.19 to 
1.90) 




32 1.10 740 0.66 
1.68 (1.18 to 
2.39) 
2.14 (1.50 to 
3.05) 
1.72 (1.20 to 
2.45) 
- Sepsis 13 0.45 383 0.34 
1.32 (0.76 to 
2.29) 
1.66 (0.96 to 
2.90) 






24 0.83 973 0.86 
0.96 (0.64 to 
1.44) 
1.06 (0.70 to 
1.59) 




17 0.59 496 0.44 
1.40 (0.7 to 
2.55) 
1.63 (0.89 to 
2.98) 
1.34 (0.74 to 
2.46) 
Statistically significant results are in bold. *Model 1:   Stratified by sex, adjusted for age and calendar period of surgery 
**Model 2: Stratified by sex and type of surgery (THA vs TKA), adjusted for age and calendar period of surgery, 
duration of surgery, history of chronic obstructive pulmonary disease, previous VTE,  previous serious infections, 















Table 3: Characteristics and risk of complications after total hip and knee arthroplasty 
among biologics-treated compared with non-biologics treated rheumatoid arthritis 







N 411 1391 
 
Female sex (%) 298 (72.5) 1028 (73.9) 0.62 




Hip 134 (32.6) 519 (37.3) 0.09 




398 (97) 1379 (99) 0.002 
Treated with csDMARD  328 (79.8) 645 (46.4) <0.001 
Prednisolone 
use 
Non-user 315 (76.6) 1256 (90.3) <0.001 
2.5 to 5.0 
milligrams 
49 (11.9) 80 (5.8) 
 
7.5 to 15.0 
milligrams 




11 (2.7) 9 (0.6) 
 
DAS28-CRP, mean (sd) 3.6 (1.2) 3.4 (1.2) 0.12 
HAQ-DI, median (IQR) 
1.38 (0.75 to 
1.88) 
1.12 (0.62 to 1.62) 0.004 
VAS pain, median (IQR) 47 (22 to 70) 50 (29 to 70) 0.50 
Chronic obstructive 
pulmonary disease, n (%) 
25 (6.1) 72 (5.2) 0.55 
Previous VTE, n (%) 12 (2.9) 54 (3.9) 0.45 
Cancer, n (%) 15 (3.6) 88 (6.3) 0.05 
History of hospitalisation 
due to infection, n (%) 
51 (12.4) 117 (8.4) 0.02 
Abbreviations: s.d, standard deviation; csDMAR , conventional synthetic disease modifying 
anti-rheumatic drug; DAS28-CRP, disease activity score using 28-joint count and C-reactive 


















Table 4. Numbers and hazard ratios (HR) of complications within 90 days of total hip or total knee arthroplasty surgery in 
patients with rheumatoid arthritis treated with biologics compared with non-biologics treated.  






 N (%) 
HR 
(95% CI) 











7 (0.5) 1 (Ref.)  8 (0.6) NA *  35 (2.5) 1 (Ref.) 
Results in bold indicate p<0.05. * The number of events were <5 in one group and thus no Cox regressions analysis was carried out.  
Abbreviations: 95 % CI, 95 % confidence interval.  
 
 
